Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05630235 · ClinicalTrials.gov registry record · Phase 1
Effects of CBD/CBD-A Oral Extract on Resting-state EEG and Neuropathic Pain Symptoms After SCI
A Phase 1 study of Neuropathic Pain and SCI - Spinal Cord Injury, sponsored by University of Miami.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT05630235: Recruiting Phase 1 study of Neuropathic Pain and SCI - Spinal Cord Injury, sponsored by University of Miami.
NCT05630235 is a Phase 1 study of Neuropathic Pain and SCI - Spinal Cord Injury that is actively recruiting participants, run by University of Miami. The registered enrollment target is 20 participants, below the 101-participant average among 35 other Neuropathic Pain trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05630235, a Phase 1 study of Neuropathic Pain and SCI - Spinal Cord Injury, is actively recruiting participants, sponsored by University of Miami.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The main purposes of this study are to (1) measure the effect of CBD/CBD-A on pain symptoms, pain intensity, pain unpleasantness, and skin sensitivity to hot and cold temperatures; and (2) measure the effect of CBD on brain electrical activity with electroencephalography (EEG).
Primary Outcome
Assess changes in pain intensity and unpleasantness of the worst neuropathic pain using a numerical rating scale from 0-10 (0 no pain and 10 worst imaginable/unpleasant pain).
Conditions Studied
Interventions
- OTHER Placebo
- DRUG CBD/CBD-A
Study Locations (1)
Florida
- Lynn Rehabilitation Center - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-06-16 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 1 |
What NCT05630235 shows while recruiting
NCT05630235 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 101-participant average among 35 other Neuropathic Pain trials with a reported enrollment target (80% lower).
The record links to 2 conditions, with Neuropathic Pain appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05630235 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT05630235 about?
NCT05630235 is a clinical study titled "Effects of CBD/CBD-A Oral Extract on Resting-state EEG and Neuropathic Pain Symptoms After SCI". The main purposes of this study are to (1) measure the effect of CBD/CBD-A on pain symptoms, pain intensity, pain unpleasantness, and skin sensitivity to hot and cold temperatures; and (2) measure the effect of CBD on brain electrical activity with electroencephalography (EEG).
What is the current status of trial NCT05630235?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2025-06-16. Estimated completion is 2026-06-30.
What conditions does trial NCT05630235 study?
This clinical trial studies the following conditions: Neuropathic Pain, SCI - Spinal Cord Injury.
What interventions are being tested in trial NCT05630235?
The interventions under investigation include: Placebo (OTHER), CBD/CBD-A (DRUG).
Who is sponsoring clinical trial NCT05630235?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05630235 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuropathic Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05630235's enrollment target sits among peer trials
20 30th of 35 higher than 6 of 35 other Neuropathic Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neuropathic Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Novel Soluble Epoxide Hydrolase Inhibitor for Neuropathic Pain in Patients With Spinal Cord Injury
RECRUITING · Phase 1
-
Effects of Smoked Marijuana on Neuropathic Pain
COMPLETED · Phase 1
-
Topical Naloxone to Diagnose Ocular Pain
COMPLETED · Phase 1
-
Tariquidar-ondansetron Combination in Neuropathic Pain
COMPLETED · Phase 1
-
Virtual Reality (VR) Self-Hypnosis Software
RECRUITING · NA
-
Neuropathic Pain and Operant Conditioning of Cutaneous Reflexes After SCI
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI